No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HOLX240621C75000
- 0.59
- +0.14+31.11%
15min DelayClose May 31 16:00 ET
0.59High0.45Low
0.50Open0.45Pre Close7 Volume419 Open Interest75.00Strike Price339.00Turnover16.77%IV2.60%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.59Time Value100Contract SizeAmericanOptions Type0.3680Delta0.1333Gamma105.40Leverage Ratio-0.0320Theta0.0138Rho38.79Eff Leverage0.0635Vega
Intraday
- 5D
- 1D
News
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Slowing Rates Of Return At Hologic (NASDAQ:HOLX) Leave Little Room For Excitement
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two trends; firstly a growing return on capital employed (ROCE) and secondly, an incre
Express News | Hologic Shares Trims Gain, Last up 0.6%; FDA Says Hologic, Inc. Recalls Biozorb Marker Due to Complications With Implanted Devices
Express News | FDA: FDA Identified Hologic's Recall of Biozorb Marker as a Class I Recall
Express News | Hologic Recalls BioZorb Marker Due To Complications With Implanted Devices
Express News | Hologic, Inc. Recalls Biozorb Marker Due To Reported Complications And Adverse Events With Implanted Devices - FDA
Comments
$Hologic(HOLX.US$ Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography 3 MINUTES AGO, 2:07 PM EDT VIA BUSINESSWIRE Collaboration Includes Robust Education and Training to Support Radiologists and Imaging Specialists Bayer and Hologic, Inc. (NASDAQ:HOLX) today announced a first-of-its-kind collaboration to deliver a coordinated solution for contrast-enhanced mammography (CEM). The two ...
1
Multiple insiders selling shares could be a red flag. The absence of insider purchases and significant selling over the last three months may suggest insiders believe the shares are overpriced. Despite high insider ownership, the lack of buying and significant selling raises concerns about the company.
Undervalued Hologic presents opportunity to accumulate stocks. Investors cautioned to consider financial health. Company's outlook suggests further growth not reflected in share price.
I've been eyeing the news on this sector and it finally gained some traction. I agree Dare is another good one
Gapping up
$Visa(V.US$ +1.1%, $MasterCard(MA.US$ +1.7% (Keybanc upgraded their ratings to overweight from from sector weight.)
$Zillow-C(Z.US$ +4% (Bank of America double upgraded the stock to buy, citing its improved growth outlook despite a challenging macroeconomic environment.)
$Hologic(HOLX.US$ +2.8% (The women's diagnostics provider reported fiscal first quarter revenue Sunday that topped its most recent guidance and Wall Str...
$Visa(V.US$ +1.1%, $MasterCard(MA.US$ +1.7% (Keybanc upgraded their ratings to overweight from from sector weight.)
$Zillow-C(Z.US$ +4% (Bank of America double upgraded the stock to buy, citing its improved growth outlook despite a challenging macroeconomic environment.)
$Hologic(HOLX.US$ +2.8% (The women's diagnostics provider reported fiscal first quarter revenue Sunday that topped its most recent guidance and Wall Str...
10
Read more